Tezampanel

DB06354InvestigationalSmall molecule

Tezampanel is an AMPA receptor antagonist.

Mechanism: NGX426 is a prodrug of tezampanel (NGX424). Tezampanel is an antagonist that binds to glutamate kainate (Glu K5) receptors, inhibiting excitatory synapases the brain.
Curator reviewed
Primary indication: Investigated for use/treatment in pain (acute or chronic) and migraine and cluster headaches.Curator reviewed
Formula / weight: C₁₃H₂₁N₅O₂ · 279.344 g/mol (avg)
Code names: LY-293,558 · NGX-424

Resolves to

Compound

Structure

InChIKeyZXFRFPSZAKNPQQ-YTWAJWBKSA-NSMILES[H][C@]1(CCC2=NN=NN2)CC[C@@]2([H])CN[C@@]([H])(C[C@@]2([H])C1)C(O)=O

Targets

What you can answer from here — as of September 21, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tezampanel, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.